SCHEMBL3011307

SCHEMBL3011307

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
CNR2 P34972 4/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK14 Q16539 1/20 0.37
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.35
MAPK1 P28482 1/20 0.35
P2RX3 P56373 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006480 0.93 LMNA (0.41) MAPTCNR2TDP1KDM4ESMN1; SMN2
SCHEMBL3019320 0.93 MAPT (0.47) MAPTCNR2TDP1KDM4ESMN1; SMN2
SCHEMBL3013134 0.91 RAB9A (0.41) MAPTKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3011356 0.90 MAPT (0.39) MAPTCNR2TDP1KDM4ESMN1; SMN2
SCHEMBL3013069 0.90 TP53 (0.40) MAPTCNR2TDP1KDM4ESMN1; SMN2
SCHEMBL3006962 0.90 SMN1; SMN2 (0.35) MAPTSMN1; SMN2NPC1RAB9ATP53
SCHEMBL3016582 0.89 MAPT (0.40) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL3008836 0.88 KMT2A (0.40) MAPTCNR2KDM4ESMN1; SMN2NPC1
SCHEMBL3012962 0.88 AOC3 (0.34) MAPTSMN1; SMN2RAB9ALMNAMEN1
SCHEMBL3004540 0.88 CNR2 (0.40) MAPTCNR2TDP1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885CNR2 2911/4885TDP1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.